Brain Imaging for HIV-Associated Thinking and Mood Disorders

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Total Enrollment

84 participants

Study Classification

OBSERVATIONAL

Study Start Date

2012-09-13

Study Completion Date

2018-04-04

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Background:

\- Human immunodeficiency virus (HIV) infection appears to cause problems with blood vessel function. These problems may add to some thinking and mood disorders found in people with HIV infection. Researchers want to evaluate HIV infected patients to see if blood vessel function contributes to thinking and mood disorders, such as early dementia and depression. To do so, they will compare study results between people with and people without HIV infection.

Objectives:

* To compare the thickness of blood vessel walls between people with and without HIV infection.
* To study the relationship between blood vessel thickness and thinking and mood disorders.

Eligibility:

* Individuals between 25 and 55 years of age who have HIV infection.
* Healthy individuals between 25 and 55 years of age.

Design:

* Participants will be screened with a physical exam and medical history. Blood and urine samples will be collected.
* Participants will have imaging studies of the brain and major blood vessels in the head and neck.
* Participants will also have neuropsychological testing. These tests will look at memory, learning and thinking ability, attention, and mood.
* Participants will have the option of coming back for repeat blood tests every six months and repeat imaging studies and neuropsychological tests every year, over 1- 4 years period.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Thinking and Memory Problems in People With HIV

NCT01875588

HIV Positive

RECRUITING

SV2A & TSPO PET Imaging Measures to Reveal Mechanisms of HIV Neuropathogenesis During Antiretroviral Therapy

NCT05586581

HIV Associated Neurocognitive Disorder HIV Dementia HIV Encephalitis +1 more

RECRUITING PHASE1/PHASE2

Prevalence and Predictors of Neurocognitive Impairment Among HIV-infected Patients

NCT00893815

HIV Infections Memory

COMPLETED

Neurocognitive Impairment and Psychiatric Comorbidities in HIV-1

NCT00476671

HIV Infections

COMPLETED

Ferumoxytol-enhanced Brain MRI in HIV-associated Neurocognitive Disorders

NCT01665846

HIV Dementia

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

With combination antiretroviral therapy, HIV/AIDS has been transformed from a progressive, usually fatal infection to a manageable chronic condition. Yet, HIV associated neurocognitive disorders (HAND) pose a significant clinical problem, even among patients with controlled HIV viremia. There is evidence of accelerated vascular aging and other vascular disorders in HIV-infected (HIV+) people, and studies suggest an association between vascular disorders and unfavorable neurocognitive outcomes. Thus, one possible contributing factor to the high rates of HANDs and depression could be vascular dysfunction, similar to vascular depression and vascular dementia that occur in elderly non-HIV+ individuals. One commonly used diagnostic marker of vasculopathy is thickening of the vessel wall. Multiple studies have already established the correlation between vessel wall thickening and vascular disease manifestations. This prospective observational study aims to examine the relationships between neurocognitive and depression outcomes and vessel wall thickness as a marker of vascular disease in HIV+ adults. We will be using neuropsychological testing, brain imaging, blood biomarkers, and state-of-the-art high-resolution MR imaging of the carotid vessel walls. HIV infected patients (n=40) and HIV-negative controls (n=40) will be recruited. Participants who consent to longitudinal follow-up will be followed for two years with clinical evaluations every 6 months and repeat imaging studies at 12 and 24 months. Cross sectional data analysis will compare markers of vascular and neurocognitive disorders between HIV-infected and HIV-negative participants. The longitudinal data analysis will assess and compare the temporal progression of vascular disease (imaging and blood biomarker findings) in relation to changes in neurocognitive and depression scores in both groups.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Human Immunodeficiency Virus Neurocognitive Impairment

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Age 25-61 years.
2. Willingness to allow stored samples, human leukocyte antigen (HLA) testing, and future genetic testing.
3. Hemoglobin less than or equal to 9.0 g/dL, HCT less than or equal to 28%, platelets less than or equal to 50,000/microL.
4. English language fluency (required for neuropsychological testing).

1. Documented HIV infection by standard HIV testing. Prior documentation of HIV- antibody status at the NIH will be accepted in lieu of repeat testing.
2. HIV viral load below the limit of detection on combination antiretroviral therapy for less than or equal to 1 year.
3. Under the care of a primary care physician.

1\. HIV-antibody negative.

Exclusion Criteria

1. Contraindication to MRI scanning, including pacemakers or other implanted electrical devices, brain stimulators, some types of dental implants, aneurysm clips (metal clips on the wall of a large artery), metallic prostheses (including metal pins and rods, heart valves, and cochlear implants), permanent eyeliner, implanted delivery pump, or shrapnel fragments.
2. Subjects with a condition precluding entry into scanner and acquisition of scans (e.g., morbid obesity, claustrophobia, back pain, motion disorders).
3. Glomerular filtration rate \<45 mL/min/1.73 m(2) as estimated using the Modified Diet in Renal Disease equation.
4. Allergy to qadolinium (MRI contrast)
5. Evidence of current or prior central nervous system opportunistic infection(s) and/or space-occupying lesions such as primary CNS lymphoma.
6. Prior history of intrathecal chemotherapy or radiation therapy to the brain.
7. History of or current diagnosis of systemic vasculitis.
8. Active systemic infection or malignancy requiring therapy.
9. Psychiatric condition interfering with ability to participate in study procedures or provide informed consent.
10. Patient or provider report of alcohol or drug abuse ongoing or within 3 months prior to participation.
11. Sickle cell disease (due to known association with vasculopathy).
12. Systolic blood pressure less than or equal to 180 mmHg at screening.
13. Persons infected with hepatitis C virus (HCV) who are being treated or planning to seek treatment for HCV.
14. Women who are lactating, pregnant, or actively seeking to become pregnant.
15. Other known clinical condition or conditions discovered on MRI that, at the discretion of the investigators, precludes serial clinical, neuropsychological, or imaging evaluation.

1\. HIV acquired perinatally (due to potential effects of HIV and antiretroviral therapy on neurocognitive and vascular development).

Minimum Eligible Age

25 Years

Maximum Eligible Age

61 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes